Media coverage about Cara Therapeutics (NASDAQ:CARA) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cara Therapeutics earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.6704294869703 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have effected Accern Sentiment’s analysis:

A number of brokerages recently weighed in on CARA. Raymond James Financial, Inc. reduced their price target on shares of Cara Therapeutics from $28.00 to $25.00 and set a “market perform” rating for the company in a research report on Thursday, August 3rd. Piper Jaffray Companies set a $27.00 price target on shares of Cara Therapeutics and gave the company a “buy” rating in a research report on Saturday, August 5th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a research report on Friday, August 4th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price target on shares of Cara Therapeutics in a research report on Wednesday, October 4th. Finally, BidaskClub cut shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $25.17.

Shares of Cara Therapeutics (NASDAQ:CARA) opened at $12.19 on Friday. Cara Therapeutics has a 1 year low of $8.61 and a 1 year high of $28.50.

Cara Therapeutics (NASDAQ:CARA) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). During the same quarter last year, the firm earned ($0.42) EPS. research analysts expect that Cara Therapeutics will post -1.84 earnings per share for the current fiscal year.

In other news, CEO Derek T. Chalmers sold 16,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the completion of the sale, the chief executive officer now directly owns 1,066,292 shares of the company’s stock, valued at $13,499,256.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 7.70% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Cara Therapeutics (CARA) Share Price” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at

Cara Therapeutics Company Profile

Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with's FREE daily email newsletter.